|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jim Cramer pinpoints the windows of opportunity in the market-wide sell-off and helps investors strategize how to play the decline.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss current headwinds for US equities, including the nomination of a new (or same) Federal Reserve Chair in a few weeks.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the New York Stock Exchange to discuss his firsthand account of what it was like on the floor that day.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the latest Q3 earnings. Disclosure: Verizon is Yahoo Finance's parent company, and Alan Valdes owns shares of the company.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Abbott Laboratories with the following peers – Pfizer Inc., Johnson & Johnson, Hologic, Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Roche Holding Ltd Genusssch., Mylan N.V., Medtronic plc, Thermo Fisher Scientific Inc. and Boston Scientific Corporation (PFE-US, JNJ-US, HOLX-US, BMY-US, AZNCF-US, RHHVF-US, MYL-US, MDT-US, TMO-US and ... Read more (Read more...)
This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $183 million.
A new software patch to fix a cybersecurity weakness in pacemakers has raised a dilemma among doctors and patients: Is the fix worth the risk?
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .
"How Moats Translate into Sustainable Competitive Advantages" is a five-part moat investing education series that explores the primary sources of economic moats.
During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.
Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.
General Motors stock has a rare combination of a breakdown valuation and zippy price momentum. That is, it trades at eight times forward earnings estimates, making it less than half as expensive as the ...
The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.